← Eichor
Condition: Myeloproliferative Syndrome Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myeloproliferative Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NA · 3 location(s) · University of Miami · NCT05745285Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099Caris Chromoseq Data Collection
Phase N/A · 1 location(s) · Caris Science, Inc. · NCT07680868Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/Phase 2 · 19 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05849662Italian Network MDS Registry
Phase N/A · 20 location(s) · Fondazione Italiana Sindromi Mielodisplastiche-ETS · NCT02808858The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Tr
Phase N/A · 1 location(s) · Nantes University Hospital · NCT06439199CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT07238712CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
NA · 1 location(s) · Children's Hospital of Philadelphia · NCT03810196211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 · 14 location(s) · Hangzhou GluBio Pharmaceutical Co., Ltd. · NCT06378437Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT06265584Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.